Afficher la notice abrégée

Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPULIDO, Marina
dc.contributor.authorROUBAUD, G.
dc.contributor.authorCAZEAU, A. L.
dc.contributor.authorMAHAMMEDI, H.
dc.contributor.authorVEDRINE, L.
dc.contributor.authorJOLY, F.
dc.contributor.authorMOUREY, L.
dc.contributor.authorPFISTER, C.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorGOBERNA, Alejandro
dc.contributor.authorLORTAL, B.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBELLERA, Carine
dc.contributor.authorPOURQUIER, P.
dc.contributor.authorHOUEDE, N.
dc.date.accessioned2020-12-15T10:33:23Z
dc.date.available2020-12-15T10:33:23Z
dc.date.issued2018-02-17
dc.identifier.issn1471-2407en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/23552
dc.description.abstractEnBACKGROUND: Bladder cancer is the 7th cause of death from cancer in men and 10th in women. Metastatic patients have a poor prognosis with a median overall survival of 14 months. Until recently, vinflunine was the only second-line chemotherapy available for patients who relapse. Deregulation of the PI3K/AKT/mTOR pathway was observed in more than 40% of bladder tumors and suggested the use of mTOR as a target for the treatment of urothelial cancers. METHODS: This trial assessed the efficacy of temsirolimus in a homogenous cohort of patients with recurrent or metastatic bladder cancer following first-line chemotherapy. Efficacy was measured in terms of non-progression at two months according to the RECIST v1.1 criteria. Based on a two-stage optimal Simon's design, 15 non-progressions out of 51 evaluable patients were required to claim efficacy. Patients were treated at a weekly dose of 25 mg IV until progression, unacceptable toxicities or withdrawal. RESULTS: Among the 54 patients enrolled in the study between November 2009 and July 2014, 45 were assessable for the primary efficacy endpoint. A total of 22 (48.9%) non-progressions were observed at 2 months with 3 partial responses and 19 stable diseases. Remarkably, 4 patients were treated for more than 30 weeks. Fifty patients experienced at least a related grade1/2 (94%) and twenty-eight patients (52.8%) a related grade 3/4 adverse event. Eleven patients had to stop treatment for toxicity. This led to recruitment being halted by an independent data monitoring committee with regard to the risk-benefit balance and the fact that the primary objective was already met. CONCLUSIONS: While the positivity of this trial indicates a potential benefit of temsirolimus for a subset of bladder cancer patients who are refractory to first line platinum-based chemotherapy, the risk of adverse events associated with the use of this mTOR inhibitor would need to be considered when such an option is envisaged in this frail population of patients. It also remains to identify patients who will benefit the most from this targeted therapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01827943 (trial registration date: October 29, 2012); Retrospectively registered.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enCIC1401
dc.subject.enEPICENE
dc.title.enSafety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer
dc.title.alternativeBMC Canceren_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1186/s12885-018-4059-5en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed29454321en_US
bordeaux.journalBMC Canceren_US
bordeaux.page194en_US
bordeaux.volume18en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamCIC1401en_US
bordeaux.teamEPICENE_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=BMC%20Cancer&rft.date=2018-02-17&rft.volume=18&rft.issue=1&rft.spage=194&rft.epage=194&rft.eissn=1471-2407&rft.issn=1471-2407&rft.au=PULIDO,%20Marina&ROUBAUD,%20G.&CAZEAU,%20A.%20L.&MAHAMMEDI,%20H.&VEDRINE,%20L.&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_BMCC_2018_Pulido.pdf
Taille:
539.2Ko
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
914octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée